Literature DB >> 835580

Lupus nephritis. Clinical course as related to morphologic forms and their transitions.

D S Baldwin, M C Gluck, J Lowenstein, G R Gallo.   

Abstract

An intensive study of the course of lupus nephritis has been undertaken in 88 patients in whom strict morphologic criteria were utilized in classification. All were treated with steroid, and 17 received cytotoxic drugs in addition. Focal proliferative lupus nephritis generally follows a benign course except in the occasional instances when transition to the diffuse proliferative or membranous forms occurs. Membranous lupus nephritis, when characterized by persistent nephrotic syndrome, leads slowly to renal failure, but this progression is aborted in the one-third in whom remission of the nephrotic syndrome can be achieved. A fatal outcome occurs within five years in the majority of those with diffuse proliferative lupus nephritis and the nephrotic syndrome, often in association with necrotizing renal vasculitis, severe hypertension and accelerated renal failure. A small number with the diffuse proliferative form have a remission and then show only mesangial abnormalities, usually, however, with the appearance of glomerular sclerosis. Progressive glomerular sclerosis is observed in some patients and may be a sequel of the remission of the diffuse or focal proliferative lesions, or it may represent still another form of lupus nephritis. Mesangial immune deposits with or without proliferation, at times in the absence of clinical renal disease, are observed early in the course of systemic lupus erythematosus (SLE) and may proceed to the diffuse proliferative or membranous forms. The present observations serve to emphasize the importance of strict morphologic classification in the comparison of different treatment regimens for lupus nephritis. In view of the grave prognosis of established diffuse proliferative lupus nephritis, which probably evolves from a mesangial involvement common to all patients with SLE from its onset, early therapy may be the key to the management of lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 835580     DOI: 10.1016/0002-9343(77)90345-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  39 in total

1.  Rapidly deteriorating kidney function in a young man previously diagnosed with membranous nephropathy.

Authors:  Giovani Gadonski; Carlos E Poli-de-Figueiredo; Fernando C Fervenza; Ajay K Singh; Fernando M Tettamanzy; Ivan C F Antonello; Domingos O d'Avila
Journal:  Nephron Clin Pract       Date:  2010-05-07

2.  Chronic immune complex disease in mice: the role of antibody affinity.

Authors:  M W Steward
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

3.  Relation between serological data at the time of biopsy and renal histology in lupus nephritis.

Authors:  J C Nossent; S C Henzen-Logmans; T M Vroom; V Huysen; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

4.  A review of glomerular ultrastructure in systemic lupus erythematosus.

Authors:  F R Comerford
Journal:  Ir J Med Sci       Date:  1977-07       Impact factor: 1.568

Review 5.  The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions.

Authors:  Suzanne Wilhelmus; Charles E Alpers; H Terence Cook; Franco Ferrario; Agnes B Fogo; Mark Haas; Kensuke Joh; Laure-Hélène Noël; Surya V Seshan; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 10.121

6.  Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus.

Authors:  M D Kazatchkine; D T Fearon; M D Appay; C Mandet; J Bariety
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

7.  Immunoglobulin classes in skin basement membrane in systemic lupus erythematosus: clinical significance and comparison with classes of serum anti-DNA antibodies.

Authors:  B Bresnihan; G M Hale; C C Bunn; G R Hughes
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

8.  The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis.

Authors:  S A Cairns; E J Acheson; C L Corbett; S Dosa; N P Mallick; W Lawler; G Williams
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

9.  Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.

Authors:  J Quddus; K J Johnson; J Gavalchin; E P Amento; C E Chrisp; R L Yung; B C Richardson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

10.  The presence and possible role of monocyte infiltration in human chronic proliferative glomerulonephritides. Light microscopic, immunofluorescence, and histochemical correlations.

Authors:  G Monga; G Mazzucco; G B di Belgiojoso; G Busnach
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.